Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Immuneering CorporationNASDAQ: IMRX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $180.76K fell 98.7% year over year, behind the +1074.3% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +2184.5% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.7% toward the trailing-twelve-month pace of +1074.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 226.58M USD
- Year-over-year change
- +4172.3%
- 4-year CAGR
- +11.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 226.58M | +4172.3% |
| FY2024 | 2024-12-31 | 5.3M | -81.4% |
| FY2023 | 2023-12-31 | 28.44M | +149558.4% |
| FY2022 | 2022-12-31 | 19K | -100.0% |
| FY2021 | 2021-12-31 | 144.26M | — |
Financing Cash Flow vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 financing cash flow of $212.95M is the largest of the 11 companies compared; the peer median is $40.08M.
- Its year-over-year change of +1074.3% is the highest of 11, against a peer median of -20.2%.
- Over three fiscal years its annual growth of +2184.5% compares with a peer median of +17.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Mar 2026 | $172.89M | +451.1% | +557.7% | 243.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $127.78M | +11.1% | — | — |
| LTM Mar 2026 | $57.73M | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $42.1M | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $1.8M | -109.8% | — | 4.0% | |
| LTM Mar 2026 | $1.3M | +41.9% | -27.5% | — | |
| LTM Mar 2026 | $637K | -99.4% | +22.8% | 11.1% | |
| LTM Mar 2026 | $569K | -68.7% | +48.1% | 4.1% | |
| Peer median (excluding IMRX) | $40.08M | -20.2% | +17.3% | 120.1% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Depreciation & Amortization | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K |
| Deferred Income Tax | (307.49K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.8M | 0 | 5.73M | 6.5M | 0 |
| Change in Working Capital | 900.42K | 1.72M | (974.64K) | (925.38K) | 3.82M |
| Accounts Receivables | 279.71K | 233.62K | 12.42K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (130.4K) | 1.76M | (1.11M) | (112.14K) | (400.8K) |
| Other Working Capital | 751.1K | (276.56K) | 119.84K | (813.24K) | 4.22M |
| Other Non-Cash Items | 130.24K | 3.9M | (601.59K) | 75.98K | 6.16M |
| Operating Cash Flow | (30.85M) | (44.1M) | (48.97M) | (55M) | (45.34M) |
| Capital Expenditures | (60.79K) | (742.49K) | (342.75K) | (84.88K) | (142.23K) |
| Acquisitions (Net) | 70.35K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (75.63M) | (50.1M) | (44.66M) | (5.41M) | (88.6M) |
| Sales of Investments | 75.62M | 92.68M | 52.3M | 31.93M | 0 |
| Other Investing Activities | (75.62M) | 0 | 0 | 0 | 247 |
| Investing Cash Flow | (75.62M) | 41.83M | 7.3M | 26.43M | (88.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 120.32M | 19K | 28.2M | 4.24M | 226.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (842.76K) | 0 | 241.07K | 1.07M | (147) |
| Financing Cash Flow | 144.26M | 19K | 28.44M | 5.3M | 226.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.8M | (2.25M) | (13.23M) | (23.26M) | 92.5M |
| Free Cash Flow | (30.91M) | (44.84M) | (49.31M) | (55.08M) | (45.49M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.